Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study☆

Annals of Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles